



Genocea Biosciences
Investor Relations Department
100 Acom Park Drive, 5th Floor
Cambridge, MA 02140
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: GNCA

Last Trade:	0.89
Trade Time:	4:00 PM ET Jan 19, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.79 - 7.29
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 17, 2018

[Genocea Biosciences, Inc. Announces Pricing of \\$55 Million Concurrent Public Offerings](#)

Jan 16, 2018

[Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants](#)

Nov 21, 2017

[Genocea to Present at 29th Annual Piper Jaffray Healthcare Conference](#)

Nov 8, 2017

[Genocea to Present at Stifel 2017 Healthcare Conference](#)

Nov 7, 2017

[Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 17, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)